CLINICA 100 TOP 10: Roche Diagnostics
This article was originally published in Clinica
Executive Summary
Roche Diagnostics remains at No 6 in our Clinica 100 and continues to hold on as leader of the IVD sector. While not the most acquisitive buyer, Roche has been a consistent shopper, adding mainly smaller, bolt-on technologies to its molecular diagnostics offering. In 2014, it made six acquisitions, mostly of undisclosed amounts or under $500m. It made the same number of acquisition in 2015, but it dug deeper in its pocket this year and signed a deal worth up to $1.2bn to gain a majority stake in Foundation Medicine, a molecular information and genomic analysis firm. See how Roche Diagnostics performed in the last five years.
Roche Diagnostics remains at No 6 in our Clinica 100 and continues to hold on as leader of the IVD sector. While not the most acquisitive buyer, Roche has been a consistent shopper, adding mainly smaller, bolt-on technologies to its molecular diagnostics offering. In 2014, it made six acquisitions, mostly of undisclosed amounts or under $500m. It made the same number of acquisition in 2015, but it dug deeper in its pocket this year and signed a deal worth up to $1.2bn to gain a majority stake in Foundation Medicine, a molecular information and genomic analysis firm. See how Roche Diagnostics performed in the last five years.
* The Clinica league tables show medtech sales for companies’ latest fiscal years, with the cut-off date being year ended June 30, 2015. For the majority of companies, the figures are for 2014 vs 2013, unless stated otherwise.